D.C.’s in recess, but there’s a lot happening. We have a look at BIO’s recent comments on FDA’s clinical trial diversity guidance, a long-awaited USDA nominee, and why Accelerated Approval is under political attack. (772 words, 3 minutes, 51 seconds)
Read More